Minerva Neurosciences, Inc. focuses on developing treatments for schizophrenia, specifically targeting negative symptoms such as loss of motivation and emotional blunting. The company is advancing roluperidone (MIN-101) as a monotherapy aimed at improving these symptoms, which have been historically overlooked in schizophrenia treatment. Minerva operates in the biopharmaceutical sector, collaborating with various partners to enhance care for individuals living with schizophrenia.
